European Journal of Clinical Pharmacology

, Volume 68, Issue 11, pp 1533–1540

Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study

  • Jean-Pascal Fournier
  • Agnès Sommet
  • Robert Bourrel
  • Stéphane Oustric
  • Atul Pathak
  • Maryse Lapeyre-Mestre
  • Jean-Louis Montastruc
Pharmacoepidemiology and Prescription

Abstract

Purpose

Non-steroidal anti-inflammatory drugs (NSAIDs) are known to antagonize the effects of antihypertensive drugs, and these associations can lead to an increase in arterial blood pressure. However, the impact of NSAIDs on hypertension treatment management in large-scale populations remains poorly evaluated. We examined whether the introduction of NSAID into the treatment regimen would induce an intensification of hypertension treatment (defined as the introduction of a new antihypertensive drug).

Methods

We conducted a cohort study involving 5,710 hypertensive subjects included in the French health insurance system database who had been treated and stabilized with their antihypertensive therapy and not exposed to any NSAID between 1 April 2005 and 1 April 2006. The maximum follow-up duration was 4 years.

Results

Adjusted hazard ratios (HR) for hypertension treatment intensification were 1.34 [95 % confidence interval (CI) 1.05–1.71] for NSAIDs in general, 1.79 (95 % CI 1.15–2.78) for diclofenac and 2.02 (95 % CI:1.09–3.77) for piroxicam. There were significant interactions between NSAIDs and angiotensin converting enzyme inhibitors (ACEIs; HR  4.09, 95 % CI 2.02–8.27) or angiotensin receptor blockers (ARBs; HR 3.62, 95 % CI 1.80–7.31), but not with other antihypertensive drugs.

Conclusions

Exposure to NSAIDs leads to an intensification of hypertension treatment, especially in patients treated with ACEIs or ARBs. Renin–angiotensin system blockers should be avoided whenever NSAIDs are prescribed.

Keywords

Anti-inflammatory agents, non-steroidal Antihypertensive agents Cohort studies Drug interactions Insurance, health, reimbursement Pharmacoepidemiology 

References

  1. 1.
    Olyaei AJ, Whelton A, Sturmer T, Porter GA (2008) Non-steroidal anti-inflammatory drugs. In: de Broe ME, Porter GA (eds) Clinical nephrotoxins: renal injury from drugs and chemicals, 3rd edn. Revue Prescrire, Paris, pp 419–457Google Scholar
  2. 2.
    Maas R, Böger RH (2003) Antihypertensive therapy: special focus on drug interactions. Expert Opin Drug Saf 2(6):549–579PubMedCrossRefGoogle Scholar
  3. 3.
    Snowden S, Nelson R (2011) The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev 19(4):184–191PubMedCrossRefGoogle Scholar
  4. 4.
    European Medicines Agency/Committee for Medicinal Products for Human Use (EMA/CHMP) (2011) European Medicines Agency starts new review of cardiovascular risks of non-selective NSAIDs. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/10/WC500116887.pdf Accessed 05 Nov 2011
  5. 5.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572, 21PubMedCrossRefGoogle Scholar
  6. 6.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HAS, Zanchetti (2007) A 2007 ESH-ESC Practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 25(9):1751–1762PubMedCrossRefGoogle Scholar
  7. 7.
    Rose AJ, Berlowitz DR, Manze M, Orner MB, Kressin NR (2009) Intensifying therapy for hypertension despite suboptimal adherence. Hypertension 54(3):524–529PubMedCrossRefGoogle Scholar
  8. 8.
    Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA (1998) Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339(27):1957–1963PubMedCrossRefGoogle Scholar
  9. 9.
    Hicks PC, Westfall JM, Van Vorst RF, Bublitz Emsermann C, Dickinson LM, Pace W, Parnes B (2006) Action or inaction? Decision making in patients with diabetes and elevated blood pressure in primary care. Diabetes Care 29(12):2580–2585PubMedCrossRefGoogle Scholar
  10. 10.
    Bolen SD, Samuels TA, Yeh H-C, Marinopoulos SS, McGuire M, Abuid M, Brancati FL (2008) Failure to intensify antihypertensive treatment by primary care providers: a cohort study in adults with diabetes mellitus and hypertension. J Gen Intern Med 23(5):543–550PubMedCrossRefGoogle Scholar
  11. 11.
    Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM (2002) Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 162(4):413–420PubMedCrossRefGoogle Scholar
  12. 12.
    Martin-Latry K, Bégaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19(3):256–265PubMedCrossRefGoogle Scholar
  13. 13.
    WHO Collaborating Centre for Drug Statistics Methodology (2011) ATC/DDD Index 2011. Available at: http://www.whocc.no/atc_ddd_index/. Accessed 5 Nov 2011
  14. 14.
    Le Gouvernement Francais (1978) Loi n°78-17 du 6 janvier 1978 relative à l’informatique, aux fichiers et aux libertés.. Available at: http://www.legifrance.gouv.fr/. Accessed 05 Nov 2011
  15. 15.
    Johnson AG, Nguyen TV, Day RO (1994) Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121(4):289–300PubMedGoogle Scholar
  16. 16.
    Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153(4):477–484PubMedCrossRefGoogle Scholar
  17. 17.
    Olkkola KT, Brunetto AV, Mattila MJ (1994) Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 26(2):107–120PubMedCrossRefGoogle Scholar
  18. 18.
    Sudano I, Flammer AJ, Périat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, Ruschitzka F (2010) Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 122(18):1789–1796PubMedCrossRefGoogle Scholar
  19. 19.
    Wilson SL, Poulter NR (2006) The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 24(8):1457–1469PubMedCrossRefGoogle Scholar
  20. 20.
    Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C, DeLucca P, Demopoulos L (2000) Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 36(3):461–465PubMedCrossRefGoogle Scholar
  21. 21.
    Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A (2002) Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 20(5):1007–1014PubMedCrossRefGoogle Scholar
  22. 22.
    Manrique C, Giles TD, Ferdinand KC, Sowers JR (2009) Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens 11(7):369–375CrossRefGoogle Scholar
  23. 23.
    Whelton A, White WB, Bello AE, Puma JA, Fort JG (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90(9):959–963, 1PubMedCrossRefGoogle Scholar
  24. 24.
    Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359(9301):118–123PubMedCrossRefGoogle Scholar
  25. 25.
    Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sørensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Køber L, Torp-Pedersen C (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85(2):190–197PubMedCrossRefGoogle Scholar
  26. 26.
    Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, Sørensen R, Folke F, Buch P, Gadsbøll N, Rasmussen S, Poulsen HE, Køber L, Madsen M, Torp-Pedersen C (2009) Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 169(2):141–149, 26PubMedCrossRefGoogle Scholar
  27. 27.
    Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM (2010) Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 69(6):689–700PubMedCrossRefGoogle Scholar
  28. 28.
    McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9):e1001098PubMedCrossRefGoogle Scholar
  29. 29.
    Samson S, Ricordeau P, Pépin S (2007) Hypertension artérielle et facteurs de risque associés: évolutions des traitements entre 2000 et 2006. Points Repère 10:1–8Google Scholar
  30. 30.
    Rossignol M, Abouelfath A, Lassalle R, Merlière Y, Droz C, Bégaud B, Depont F, Moride Y, Blin P, Moore N, Fourrier-Réglat A (2009) The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. Br J Clin Pharmacol 67(1):118–124PubMedCrossRefGoogle Scholar
  31. 31.
    Fosbøl EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sørensen R, Rasmussen JN, Køber L, Madsen M, Torp-Pedersen C (2008) The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 17(8):822–833PubMedCrossRefGoogle Scholar
  32. 32.
    Noize P, Bazin F, Dufouil C, Lechevallier-Michel N, Ancelin M-L, Dartigues J-F, Tzourio C, Moore N, Fourrier-Réglat (2009) A Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf 18(4):310–319PubMedCrossRefGoogle Scholar
  33. 33.
    Takahashi Y, Nishida Y, Asai S (2012) Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 68:123–129. doi:10.1007/s00228-011-1088-2 Google Scholar
  34. 34.
    Nicodème R, Albessard A, Amar J, Chamontin B, Lang T (2009) Poor blood pressure control in general practice: in search of explanations. Arch Cardiovasc Dis 102(6–7):477–483PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jean-Pascal Fournier
    • 1
    • 2
    • 3
  • Agnès Sommet
    • 1
    • 2
    • 4
  • Robert Bourrel
    • 5
  • Stéphane Oustric
    • 3
  • Atul Pathak
    • 1
    • 4
    • 6
  • Maryse Lapeyre-Mestre
    • 1
    • 2
    • 4
  • Jean-Louis Montastruc
    • 1
    • 2
    • 4
  1. 1.Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MédecineUniversité Paul SabatierToulouseFrance
  2. 2.INSERM, UMR1027ToulouseFrance
  3. 3.Département Universitaire de Médecine Générale, Faculté de MédecineUniversité Paul SabatierToulouseFrance
  4. 4.Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Information sur le MédicamentCentre Hospitalier Universitaire de ToulouseToulouseFrance
  5. 5.Direction Régionale du Service Médical Midi-Pyrénées (CNAMTS)ToulouseFrance
  6. 6.INSERM UMR1048ToulouseFrance

Personalised recommendations